Figure 3From: The efficacy and safety of once-daily quetiapine extended release in patients with schizophrenia switched from other antipsychotics: an open-label study in Chinese populationChanges in PANSS total and subscale scores from baseline to week 12 in patients with schizophrenia receiving the treatment of switching to quetiapine XR. The change in PANSS total and subscales score in all patients shown is based on estimated marginal means. *p < .05.Back to article page